Back to Authors

Shah, Meera

https://orcid.org/0000-0002-5359-336X

A5020872528 | I1330342723

Mayo Clinic

Citations 267

Differential Impact on Survival in Myeloid Neoplasm Patients with U2AF1 Mutations

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9602-9603

10.1182/blood-2022-167405

TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9798-9799

10.1182/blood-2022-165859

Characteristics and Outcomes of Radiation Therapy-Related Myeloid Neoplasms

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6309-6311

10.1182/blood-2022-164769

Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3-Mutated Acute Myeloid Leukemia (AML)

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9019-9020

10.1182/blood-2022-168303

Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1286-1287

10.1182/blood-2022-165491

Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10942-10944

10.1182/blood-2022-164785

High Prevalence of Epigenetic Mutations in Histiocytic and Dendritic Cell Disorders: Results from Molecular Analysis of a Large Cohort from Histiocytosis Working Group

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 32-33

10.1182/blood-2022-162855

Prevalence and Impact of Clonal Hematopoiesis in Therapy Related Myeloid Neoplasms Occurring in the Context of Low-Grade Follicular Lymphoma Treated with Radioisotope Therapy

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 11403-11405

10.1182/blood-2022-165124

Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6962-6963

10.1182/blood-2022-167978

Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53therapy-Related Myeloid Neoplasm Patients with Poor Outcome

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6964-6965

10.1182/blood-2022-168349